Incyte's pancreatic cancer drug shows lasting tumor responses — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Incyte advanced its pancreatic cancer drug into a late-stage clinical trial after reporting that the therapy, when combined with chemotherapy, induced lasting tumor responses in certain patients
- Revolution Medicines previously gained approval for Rasonque, the first pancreatic cancer drug targeting RAS mutations to demonstrate survival benefits, setting a new benchmark in the field
- Incyte, Verastem, and Hengrui are developing next-generation therapies that selectively target specific RAS gene mutations, aiming to improve upon current treatment outcomes
- RAS gene mutations, long considered undruggable, are now the focus of multiple biotech efforts following clinical validation that targeting them can yield meaningful patient responses
Why it matters: Pancreatic cancer patients with RAS mutations now have a growing pipeline of targeted therapies in development after Incyte and others demonstrated clinical responses, shifting the standard of care toward precision oncology and increasing competitive pressure to refine mutation-specific treatments.
Ask SkimNews
